{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:02:58Z","timestamp":1747465378413,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Osaka Gastrointestinal Cancer Chemotherapy Study Group"},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients aged \u226565 years and considered unsuitable for intensive chemotherapy or aged \u226576 years were enrolled. Primary tumors located from the cecum to the transverse colon were considered right-sided tumors (RSTs); those located from the splenic flexure to the rectum were considered left-sided tumors (LSTs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 36 enrolled patients, 34 were included in the efficacy analysis, with 26 and 8 having LSTs and RSTs, respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8-24.3), respectively. Although no significant differences existed in PFS between patients with LST and RST {6.6 (95% CI, 5.4-11.5) vs. 4.9 months [95% CI, 1.9-not available (NA), P = .120]}, there were significant differences in OS [19.3 (95% CI, 14.2-NA) vs.12.3 months (95% CI, 9.9-NA), P = .043].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac145","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T22:26:09Z","timestamp":1660170369000},"page":"e565-e574","source":"Crossref","is-referenced-by-count":2,"title":["The Phase II Study of Panitumumab in Chemotherapy-Na\u00efve Frail or Elderly Patients with <i>RAS<\/i> Wild-type Colorectal Cancer: OGSG 1602 Final Results"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-8730","authenticated-orcid":false,"given":"Tetsuji","family":"Terazawa","sequence":"first","affiliation":[{"name":"Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University , Takatsuki-City, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, National Hospital Organization Osaka National Hospital , Higashiosaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Goto","sequence":"additional","affiliation":[{"name":"Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University , Takatsuki-City, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Higashiosaka City Medical Center , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kobe City Medical Center General Hospital , Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Noura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka Rosai Hospital , Sakai, Japan"},{"name":"Department of Gastroenterological Surgery, Toyonaka Municipal Hospital , Toyonaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kansai Rosai Hospital , Amagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine , Osakasayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kansai Electric Power Hospital , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsushi","family":"Shingai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Saiseikai Senri Hospital , Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sakai City Medical Center , Sakai , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Kotaka","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Center, Sano Hospital , Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hiraki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Itami City Hospital , Itami, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hyogo Prefectural Nishinomiya Hospital , Nishinomiya, Hyogo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Nakae","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mimihara General Hospital , Sakai , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine , Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-0132","authenticated-orcid":false,"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University , Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Tsujinaka","sequence":"additional","affiliation":[{"name":"Cancer Center, Izumi City General Hospital , Izumi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine , Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"issue":"1","key":"2023070520011884500_CIT0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ONCO.13523","article-title":"Phase II study of panitumumab monotherapy in chemotherapy-na\u00efve frail or elderly patients with unresectable RAS wild-type colorectal cancer: OGSG 1602","volume":"26","author":"Terazawa","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"2023070520011884500_CIT0002","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","article-title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","volume":"51","author":"Brul\u00e9","year":"2015","journal-title":"Eur J Cancer"},{"issue":"10","key":"2023070520011884500_CIT0003","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"2023070520011884500_CIT0004","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1152\/physiolgenomics.00185.2006","article-title":"Map of differential transcript expression in the normal human large intestine","volume":"33","author":"LaPointe","year":"2008","journal-title":"Physiol Genomics"},{"key":"2023070520011884500_CIT0005","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2019.09.008","volume":"123","author":"Soldevilla","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"2023070520011884500_CIT0006","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/aje\/kwj063","article-title":"The inconsistency of \u201coptimal\u201d cutpoints obtained using two criteria based on the receiver operating characteristics curve.","volume":"163","author":"Perkins","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2023070520011884500_CIT0007","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2023070520011884500_CIT0008","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/annonc\/mdx816","article-title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial","volume":"29","author":"Yamada","year":"2018","journal-title":"Ann Oncol"},{"issue":"17","key":"2023070520011884500_CIT0009","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2023070520011884500_CIT0010","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"Peak: a randomized, multicenter phase ii study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mfolfox6) or bevacizumab plus mfolfox6 in patients with previously untreated, unresectable, wild-type kras exon 2 metastatic colorectal cancer","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"issue":"20","key":"2023070520011884500_CIT0011","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.24527","article-title":"Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.","volume":"115","author":"Sorbye","year":"2009","journal-title":"Cancer."},{"issue":"3","key":"2023070520011884500_CIT0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2023070520011884500_CIT0013","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/ijc.27871","article-title":"Increasing prevalence of comorbidity in patients with colorectal cancer in the South of the Netherlands 1995\u20132010","volume":"132","author":"van Leersum","year":"2013","journal-title":"Int J Cancer"},{"issue":"15","key":"2023070520011884500_CIT0014","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.ejca.2010.04.026","article-title":"Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome","volume":"46","author":"Aarts","year":"2010","journal-title":"Eur J Cancer"},{"issue":"11","key":"2023070520011884500_CIT0015","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9779","key":"2023070520011884500_CIT0016","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet."},{"issue":"1","key":"2023070520011884500_CIT0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"2023070520011884500_CIT0018","doi-asserted-by":"crossref","first-page":"299","DOI":"10.6004\/jnccn.2014.0027","article-title":"Moving forward with expanding to an \u201call-RAS mutational analysis\u201d in metastatic colorectal cancer: beyond KRAS mutations","volume":"12","author":"Bekaii-Saab","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2023070520011884500_CIT0019","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12885-021-08271-z","article-title":"Clinical and prognostic features of patients with detailed RAS\/BRAF-mutant colorectal cancer in Japan","volume":"21","author":"Ikoma","year":"2021","journal-title":"BMC Cancer"},{"issue":"11","key":"2023070520011884500_CIT0020","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ejca.2015.04.013","article-title":"First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours","volume":"51","author":"Sastre","year":"2015","journal-title":"Eur J Cancer"},{"issue":"11","key":"2023070520011884500_CIT0021","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1634\/theoncologist.2015-0171","article-title":"Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up New Hope","volume":"20","author":"Pietrantonio","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"2023070520011884500_CIT0022","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","article-title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies","volume":"28","author":"Boeckx","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"2023070520011884500_CIT0023","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type Metastatic Colorectal Cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol"},{"issue":"14","key":"2023070520011884500_CIT0024","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","article-title":"Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)","volume":"51","author":"Heinemann","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"2023070520011884500_CIT0025","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/annonc\/mdv112","article-title":"Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"2023070520011884500_CIT0026","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clcc.2020.06.005","article-title":"Impact of size and location of metastases on early tumor shrinkage and depth of response in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label phase 3 trial FIRE-3\/AIO KRK-0306","volume":"19","author":"Froelich","year":"2020","journal-title":"Clin Colorectal Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/e565\/50825955\/oyac145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/e565\/50825955\/oyac145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T20:01:54Z","timestamp":1688587314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/7\/e565\/6659959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,8,10]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac145","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,8,10]]}}}